ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
June 29, 2021

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

ADA 2021: Study Finds Hospitalization Rates for New-onset Pediatric T2D Doubled During Pandemic
June 25, 2021

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

ADA Virtual Meeting Will Offer 5 Symposia on Latest COVID-19 Findings
June 24, 2021

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

Novel “Smart” Pen Cap for Insulin Dosing Receives FDA Clearance in Patients with Diabetes
June 24, 2021

The novel Bigfoot Unity Diabetes Management System could help improve insulin dosing in patients with type 1 or type 2 diabetes.

CGM vs SMBG in Primary Care: What Does the T2D Evidence Say?
June 17, 2021

Patients with T2D see significant improvement in glycemic control using continuous glucose monitoring. MOBILE study lead author Thomas W. Martens, MD, highlights the evidence.

8 Questions on T2 Diabetes Risk Assessment Using Prediabetes Subphenotypes
June 16, 2021

Assessment of prediabetes subphenotypes is a novel approach to better screening, prevention, and treatment for patients at risk of progression to T2D. Find out how much you know about it.

CGM Improves Glycemic Control in Patients with T2D on Basal Insulin Alone
June 04, 2021

MOBILE study group: in patients with type 2 diabetes on a less intensive insulin regimen, CGM use lowered A1c and increased time in target glucose range vs traditional blood glucose monitoring.

Bariatric Surgery Associated with Reduced Mortality in Patient with T2D, Obesity
April 28, 2021

Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.

Study: GLP-1 Receptor Agonist Therapy Reduces Asthma Exacerbations in Adults with Asthma, T2D
April 26, 2021

New findings suggest that patients with asthma and type 2 diabetes who use GLP-1 RAs for diabetes treatment intensification have fewer asthma exacerbations compared to other diabetes drugs.

Lifestyle Counseling in Primary Care Setting May Reduce Incidence of T2D in High-risk Patients
April 08, 2021

A recent study showed lifestyle counseling in primary care was effective in preventing type 2 diabetes in long-term follow-up.